Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc. (CLRB: Nasdaq) is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapeutics. The company's website is www.cellectar.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cellectar Biosciences, Inc. does
In the company’s own words
Cellectar Biosciences, Inc. (CLRB: Nasdaq) is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted cancer therapeutics. The company's website is www.cellectar.com.
The company's core objective centers on leveraging its proprietary phospholipid ether drug conjugate platform, known as PDC, to develop cancer-targeting treatments designed to deliver improved efficacy and better safety profiles through reduced off-target effects. This platform technology is engineered to provide selective delivery of diverse oncologic payloads to cancerous cells by exploiting a metabolic pathway utilized by nearly all tumor cell types, allowing PDCs to bind to specialized membrane microdomains and directly enter the intracellular compartment while avoiding lysosomes.
Cellectar's three lead programs represent different radioisotope approaches. CLR 125 is an iodine-125 Auger-emitting radioconjugate prepared to enter clinical trials in 2025, with preclinical data showing strong activity in triple negative breast cancer models. CLR 225 is an actinium-225 based alpha-emitting program demonstrating activity in pancreatic, colorectal, and breast cancer models. Iopofosine I-131, a beta-emitting iodine-131 based program, represents the company's most advanced candidate with extensive clinical development. In June 2025, the FDA granted Breakthrough Therapy Designation for iopofosine as a monotherapy for relapsed/refractory Waldenstrom macroglobulinemia, and the European Medicines Agency's Scientific Advice Working Party indicated that conditional marketing authorization filing could be acceptable.
The CLOVER WaM Phase 2 study of iopofosine in Waldenstrom macroglobulinemia patients achieved a major response rate of 58.2 percent, significantly exceeding the FDA's agreed-upon statistical hurdle of 20 percent. The company has also conducted clinical studies in multiple myeloma, non-Hodgkin's lymphoma, pediatric cancers, and head and neck cancer. Beyond radioconjugates, Cellectar is developing small molecule phospholipid drug conjugates with novel payloads and linkers, as well as exploring peptide and oligonucleotide delivery capabilities through research collaborations. The company maintains orphan drug designations for iopofosine across multiple indications and holds European SME status, providing significant regulatory and financial incentives for development and commercialization activities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1279704
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cellectar Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cellectar Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cellectar Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cellectar Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cellectar Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”